MedBulletinsAura Celeste
General surgery

Monthly general surgery bulletin — September 16, 2026

🎧 Listen to this issueAudio newscast · 6:49 min

GENERAL SURGERY BULLETIN — week of September 9–16, 2026

Moderate-volume week: 8 verified items. The only item from outside North America/Western Europe is the Brazilian meta-analysis.

Abdominal wall and hernias

1. Prophylactic mesh to prevent incisional hernia in hepatobiliopancreatic surgery

[Clinical trial] [Spain]
Randomized, prospective, double-blind trial from the Seville group (Bellido-Luque, Morales-Conde, Nogales Muñoz), published online in JAMA Surgery on September 9 (Virgen Macarena Hospital, July 2020–December 2024). 144 patients with at least two hernia risk factors undergoing open right subcostal surgery were randomized (139 after 5 intraoperative exclusions): conventional closure vs. synthetic mesh-reinforced closure. Radiological incisional hernia at 12 months 5.2% with mesh vs. 21% without; at 24 months 8.1% (4/49) vs. 37.5% (18/48). No differences in surgical site occurrences, complications or postoperative pain; better functional recovery with mesh. A J incision was associated with more hernia.
Why it matters: this is the heaviest-weight item of the week and provides dedicated data for the subcostal incision, unlike PRIMA's midline laparotomy; a single-center trial with loss to follow-up at 24 months (97 of 139 analyzed).
https://jamanetwork.com/journals/jamasurgery/article-abstract/2853952

2. Women have more complications but report better quality of life after elective ventral hernia repair

[Publication] [USA]
Retrospective cohort from the ACHQC registry (2012–2023), 32,956 elective clean-wound ventral hernia repairs (46.7% women). Women vs. men: surgical site infection 2.4% vs. 1.6% (adjusted OR 1.31; 95% CI 1.12–1.55), readmission 3.2% vs. 2.5% (not significant after adjustment: OR 1.13; 95% CI 0.99–1.3), pragmatic 2-year recurrence 19.2% vs. 15.5%. Greater unadjusted HerQLes improvement at one year (median 30 vs. 26.7); after multivariable adjustment, female sex was associated with worse 1-year HerQLes (β −1.83; 95% CI −3.55 to −0.11) and more pain. Surgical Endoscopy, September 11; oral presentation at SAGES 2026.
Why it matters: a voluntary, retrospective registry, but the size makes it necessary to incorporate sex into consent and into stratification of abdominal-wall trials.
https://link.springer.com/article/10.1007/s00464-026-13217-2

3. Perineal hernia after minimally invasive versus open abdominoperineal resection

[Meta-analysis] [Brazil]
Systematic review and meta-analysis (PROSPERO CRD420261422529) from Universidade São Caetano do Sul: 4 retrospective comparative studies, 763 patients (249 minimally invasive vs. 514 open). Perineal hernia OR 4.13 (95% CI 2.24–7.61), I² 0%; Bayesian analysis with 99.9% probability of higher risk with the minimally invasive route. Less bleeding (−156 mL) and shorter operative time (−42 min) with the minimally invasive route. Hernia, September 9, open access.
Why it matters: only 4 retrospective series with heterogeneous follow-up, but the signal is consistent and supports planned perineal reconstruction (mesh or flap) after laparoscopic or robotic APR. (Source in English, Brazilian authors.)
https://link.springer.com/article/10.1007/s10029-026-03841-1

Hepatobiliary and pancreas

4. Mesh-reinforced duct-to-mucosa pancreaticojejunostomy and clinically relevant pancreatic fistula

[Publication] [Spain / United Kingdom]
Retrospective cohort from Hospital General de Albacete (pancreaticoduodenectomy for adenocarcinoma, 2017–2022) with reinforcing mesh, adhesive and ductal stent, plus a meta-analysis of 10 studies and 1,013 patients. Pooled clinically relevant fistula 6.5% (95% CI 3.7–9.3); versus the conventional technique OR 0.35 (95% CI 0.15–0.80); length of stay 11.9 vs. 20.1 days. No differences in bile leak, delayed gastric emptying, hemorrhage or mortality. Ann Hepatobiliary Pancreat Surg, September 15.
Why it matters: the authors themselves conclude the evidence is insufficient and heterogeneous; a hypothesis for a trial, not a reason to change technique.
https://www.ahbps.org/journal/view.html?doi=10.14701/ahbps.26-150

Colorectal and digestive oncology

5. EAGLE-2: digital training in safe anastomosis and leak after right colectomy

[Publication] [International, 60 countries]
International prospective cohort (ESCP and NIHR Global Surgery Unit), 332 hospitals, 2,875 right hemicolectomies/ileocecal resections with a single anastomosis (June–September 2024). 30-day leak or collection 9.1% when the surgeon had completed the five free modules (90 min) of the EAGLE program vs. 16.4% without training; adjusted OR 0.56 (95% CI 0.41–0.78); also less reoperation (OR 0.64) and readmission (OR 0.65); mortality 2.9% vs. 5.0%. BJS, September 11, open access.
Why it matters: not randomized, and the untrained group had more emergencies (24% vs. 15%), but the magnitude and near-zero cost make it reasonable to ask the whole colorectal team, including residents, to take the course.
https://academic.oup.com/bjs/article/113/9/znag107/8790652

6. Compliance with Commission on Cancer standard 5.7 and technical quality in rectal cancer

[Publication] [USA]
National cohort (NCDB, 2020–2023) of 22,688 patients with stage I–III rectal adenocarcinoma operated on at 873 centers; 91% at hospitals meeting standard 5.7 (synoptic report of the mesorectal excision). Positive circumferential margin 12% vs. 14% (adjusted OR 0.82; 95% CI 0.68–0.99), incomplete mesorectal excision 9% vs. 14%, higher likelihood of complete mesorectum (OR 1.63). JACS, August 2026; featured in ACS Brief on September 15.
Why it matters: an association in an administrative database with no long-term oncologic outcome, but it supports the idea that systematically auditing the specimen improves technique.
https://www.facs.org/for-medical-professionals/news-publications/news-and-articles/acs-brief/september-15-2026-issue/coc-rectal-cancer-standard-compliance-signals-higher-surgical-quality/

7. Circulating tumor DNA in colon cancer: prognostic, yes — treatment guide, not yet

[Publication] [USA]
Review by the ACS colorectal Advisory Council (K. Mathis) of current data: postoperative positivity associated with about 10 times more recurrence (GALAXY); 5-year disease-free survival 28% vs. 77% (Alliance N0147); in DYNAMIC-III, de-escalation in ctDNA-negative patients did not reach non-inferiority (3-year DFS 85% vs. 88%) and escalation in positive patients did not improve outcomes. ACS Brief, September 15.
Why it matters: the test is prognostic but not predictive; NCCN does not recommend using it to decide adjuvant therapy or surveillance outside trials.
https://www.facs.org/for-medical-professionals/news-publications/news-and-articles/acs-brief/september-15-2026-issue/ctdna-predicts-colon-cancer-recurrence-but-treatment-questions-remain/

Trauma, emergency surgery and bariatrics

No verifiable items this week: no trial, multicenter cohort or guideline dated between September 9 and 16 met the bar.

General oncologic surgery

No verifiable items this week in breast, thyroid, melanoma, sarcoma or carcinomatosis.

Cross-cutting

8. Medtronic obtains FDA clearance for the LigaSure RAS Maryland on the Hugo robot

[FDA regulatory / Industry] [USA]
September 16 announcement: the first LigaSure instrument operated from a robotic console; seals and divides vessels and lymphatics up to 7 mm in about 2 seconds, only with the Valleylab FT10 generator. Already in use in Europe under CE mark since 2025. Hugo remains cleared in the US only for urology; 510(k) applications for general surgery (including hernia) and gynecology, whose filing Medtronic announced on June 3, remain pending.
Why it matters: a manufacturer release with no new clinical data; relevant only as a signal that the platform is preparing for general surgery in the US. (Official Medtronic release at the second link.)
https://www.unite.ai/medtronic-wins-fda-clearance-for-ligasure-ras-maryland-on-hugo-robot/
https://news.medtronic.com/2026-09-16-Medtronic-announces-FDA-clearance-for-LigaSure-TM-RAS-Maryland-instrument-on-the-Hugo-TM-RAS-system

Upcoming meetings and dates

ACS Clinical Congress 2026 (October; confirm dates and venue at http://facs.org/for-medical-professionals/conferences-and-meetings/clinical-congress-2026/). No other society dates were verified for the coming four weeks.

Automated curation. Always verify the primary source before applying any data to clinical practice.

Get every issue by email

Free. One email with each new issue, with a short summary and links to the page and the audio. No ads inside the content: any sponsor is identified and has no say in the selection. We do not share your data; unsubscribe with a single message.